SOX2 has been reported to play a pivotal role in developing drug resistance of glioma (11, 38) and its expression was correlated with the grade of malignancy and favored the maintenance of an undifferentiated state of cancer stem cells (39, 40). Here, SOX2 is linked to central nervous system cancer.